Veritas Pharma Inc., a Vancouver-based pharmaceutical company, announced today the appointment of David Alexander as the company’s CFO. Alexander will be responsible for leading the company’s financial strategy and operations, supporting all functions of the organization.
"I am pleased to have David join Veritas at this time in our development,” said Dr. Lui Franciosi, CEO of Veritas. “David is a strong leader whose broad experience in small and large specialty pharmaceutical organizations uniquely qualifies him to lead and build our financial operations as we enter a transformative period in our company. Having previously managed financial planning, analysis and strategic growth initiatives for a variety of Exchange Listed companies, David has a thorough understanding of the exciting opportunities from which Veritas is poised to benefit."
Growing Market Share Through Streamlining Cannabis Development
Veritas Pharma is focused on using their knowledge to streamline the development of cannabis-based treatments to capture considerable market share. The company is developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, nausea, and epilepsy.
Previous to this significant operational milestone, the company announced, earlier this month, the appointment of Dr. Domenico Spina as a director of the company. Furthermore, through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., Veritas Pharma applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations.
By continuing to strengthen their leadership team, Veritas Pharma is positioned to successfully bring additional expertise and growth opportunities to the cannabis market. "The company is approaching a period of immense growth and opportunity. I look forward to working with the Veritas team to successfully execute on the goals ahead and to focus on driving significant shareholder return,” stated David Alexander, Veritas Pharma’s newly appointed CFO.
For more information about Veritas Pharma, visit www.veritaspharmainc.com.
In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. has been compensated 137,500 common shares plus warrants by Veritas Pharma, Inc. for its profile in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer